ACE2 and COVID-19: The severity of COVID-19 in patients with diabetes, hypertension or other chronic diseases, may respond to activation of the RAS system in different tissues, leading to a compromised innate immunity, an inappropriate and elevated proinflammatory cytokine response and a low expression of ACE2.